Verastem
As of the edition of 20 October 2026, Verastem runs 8 drugs, 4 of them marketed; it is on route A at 5 targets and on route B at 0 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 4 |
| Active | 1 |
| Went quiet | 1 |
| Stopped | 2 |
| Total | 8 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Avelumab | Ends 2029 (computed from the first US licence) | 1 |
| Duvelisib | Ends 2032 (patent) | 2 |
| Defactinib | none listed | 0 |
| Avutometinib | Ends 2032 (exclusivity) | 1 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 5 targets, route B at 0 targets.
| Target | Route |
|---|---|
| PIK3CG Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform | Route A |
| PIK3CB Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform | Route A |
| PIK3CA Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform | Route A |
All 5 rows on route A or B
In the product5 company-target rows on route A or B; 2 are not shown here, and no score is.
See all 5 targets where Verastem needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Cancer: 21 trials led
- Hormones: 9 trials led
- Lungs and airways: 8 trials led